InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “mRNA Post-Transcriptional Enzymatic Capping Market“-, By Product Type (Capping Enzymes, Capping Kits, Reagents and Consumables, Custom mRNA Synthesis Services), By Application (mRNA Vaccines, mRNA Therapeutics, Research Tools, Emerging Applications), By End-User (Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations (CDMOs), Academic & Research Institutes, Contract Research Organizations (CROs)), and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034.”
Global mRNA Post-Transcriptional Enzymatic Capping Market Size is predicted to develop a 6.8% CAGR during the forecast period from 2025 to 2034.
Get A Free Report Brochure: https://www.insightaceanalytic.com/request-sample/3104
mRNA post-transcriptional enzymatic capping is a laboratory method used to add a 5′ cap structure to messenger RNA (mRNA) after in vitro transcription, closely mimicking the natural capping process in eukaryotic cells. The market encompasses post-transcriptional enzymatic capping performed using traditional enzymatic capping, optimized enzymatic systems, and advanced enzymatic systems. The latest optimized enzymatic systems (e.g., using Vaccinia virus capping enzymes) add Cap 0 or Cap 1 post-transcriptionally with an efficiency of 80-90%.
mRNA capping step is critical for the stability, translation, and cellular recognition of mRNA, particularly in therapeutic applications. The use of enzymes such as vaccinia capping enzyme (VCE), which carries out guanylyltransferase and N7-methyltransferase activities, enables the formation of the Cap-0 structure. To further enhance the mRNA’s functionality, 2′-O-methyltransferase is used to convert Cap-0 to Cap-1 by methylating the ribose of the first nucleotide. This Cap-1 structure closely resembles endogenous mRNA caps, thereby reducing innate immune activation by evading sensors such as RIG-I and MDA5. The result is authentic, biologically relevant cap structures that ensure high capping efficiency while improving mRNA stability and translation efficiency in eukaryotic cells.
The role of 2′-O-methyltransferase (2′-O-MTase) in the mRNA post-transcriptional enzymatic capping market is pivotal, as it enables the formation of Cap-1 structures, which are essential for the efficacy, stability, and safety of mRNA therapeutics and vaccines. By methylating the ribose of the first transcribed nucleotide, 2′-O-MTase helps mRNA evade innate immune sensors such as RIG-I and MDA5, thereby reducing immunogenicity and enhancing both stability and translational efficiency. These features are crucial for ensuring the therapeutic performance of mRNA-based vaccines and gene therapies. As the demand for immunologically optimized mRNA continues to rise, so does the need for high-quality 2′-O-methyltransferase enzymes. Stringent regulatory standards and the growing demand for GMP-compliant, pharmaceutical-grade reagents continue to drive this trend. In response, manufacturers are expanding production capabilities and scaling up platforms to deliver consistent, high-efficiency enzymatic capping solutions tailored to clinical and commercial mRNA applications.
List of Prominent Players in the mRNA Post-Transcriptional Enzymatic Capping Market:
- New England Biolabs (NEB)
- Takara Bio Inc.
- Canvax Biotech
- CELLSCRIPT
- Thermo Fisher Scientific
- Aldevron
- KACTUS
- Creative Biolabs
- Jena Bioscience
- Promega Corporation
Market Dynamics:
Drivers:
Governments and private companies are investing billions into mRNA research and development infrastructure, significantly accelerating the growth of the mRNA post-transcriptional enzymatic capping market. Pharmaceutical and biotech companies are increasingly turning to contract development and manufacturing organizations (CDMOs) for specialized enzymatic capping expertise, which supports scalability and efficiency in therapeutic production. The growing demand for individualized cancer vaccines and gene therapies has highlighted the need for precise and adaptable capping technologies, which enzymatic capping platforms are uniquely positioned to provide. Furthermore, the global success of COVID-19 mRNA vaccines has sparked sustained interest and investment in capping technologies, driving their application across a broadening spectrum of diseases, including oncology, personalized medicine, and infectious diseases such as influenza and RSV.
Order this Premium Report: https://www.insightaceanalytic.com/select-license/mrna-post-transcriptional-enzymatic-capping-market/3104
Challenges:
Pharmaceutical-grade capping enzymes, such as vaccinia capping enzyme and 2′-O-methyltransferase, are expensive to produce and purify to clinical-grade quality. The overall cost of mRNA production is elevated due to the need for multiple enzymatic steps, quality controls, and regulatory compliance.
Regional Trends:
North America holds the largest share of the mRNA post-transcriptional enzymatic capping market, driven by its advanced biotechnology infrastructure and strong government and private investment. Major pharmaceutical and biotech companies, along with contract development and manufacturing organizations (CDMOs), are heavily involved in the production of mRNA vaccines and therapeutics. However, the Asia-Pacific region is emerging as the fastest-growing, led by China, Japan, South Korea, and India. Governments are investing in domestic mRNA manufacturing capacity and raw material independence, including local production of enzymes and reagents. Favourable policies, expanding biotech sectors, and rising demand for vaccines and gene therapies are fueling regional growth. India and China are also strengthening their contract development and manufacturing organization (CDMO) infrastructure to attract global outsourcing for enzymatic mRNA processing.
Recent Developments:
- In August 2022, New England Biolabs (NEB) revealed the Faustovirus Capping Enzyme (FCE). This mRNA capping solution supports the manufacturing needs of mRNA therapeutics by combining high activity with a wide temperature range. All of the enzymatic activity required to produce a Cap-0 structure, a crucial stage in the maturation of eukaryotic mRNA, is present in FCE, a single-subunit enzyme. In a one-pot procedure, users can produce a Cap-1 structure when combined with NEB’s mRNA Cap 2´-O-Methyltransferase. The business added FCE, an enzyme found at NEB, to one of its mRNA synthesis products. This new product provides a simplified, scalable, and economical mRNA capping method for medicinal and research uses.
Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customization/3104
Segmentation of mRNA Post-Transcriptional Enzymatic Capping Market.
Global mRNA Post-Transcriptional Enzymatic Capping Market – By Product Type
- Capping Enzymes
- Reagents and Consumables
- Capping Kits
- Custom mRNA Services
Global mRNA Post-Transcriptional Enzymatic Capping Market – By application
- mRNA Vaccines
- mRNA Therapeutics
- Research Tools
- Emerging Applications
Global mRNA Post-Transcriptional Enzymatic Capping Market – By End-User
- Pharmaceutical & Biotechnology Companies
- Contract Development & Manufacturing Organizations (CDMOs)
- Academic & Research Institutes
- Contract Research Organizations (CROs)
Global mRNA Post-Transcriptional Enzymatic Capping Market – By Region
• North America (USA, and Canada)
• Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)
Details insights on this market: https://www.insightaceanalytic.com/report/mrna-post-transcriptional-enzymatic-capping-market/3104
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact US:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
